Envoy Medical Announces Closing of Up to $78.0 Million Upsized Public Offering

Core Viewpoint - Envoy Medical has successfully closed a public offering, raising approximately $30 million, with potential additional proceeds of up to $48 million from milestone-linked warrants, which reflects strong investor confidence in the company's cochlear implant technology [1][2][4]. Financial Details - The offering consisted of 75 million shares of Class A common stock at a price of $0.40 per share, along with Series A-1 and Series A-2 common warrants [1][4]. - The net proceeds from the offering are expected to extend the company's cash runway into the second half of 2027, beyond the anticipated submission of the Premarket Approval (PMA) application [2][5]. Warrant Information - Series A-1 common warrants have an exercise price of $0.40 per share and will expire 24 months after stockholder approval or 30 days after the PMA submission announcement [3]. - Series A-2 common warrants also have an exercise price of $0.40 per share, expiring 60 months after stockholder approval or 30 days after FDA approval announcement [3]. Use of Proceeds - The company plans to utilize the net proceeds for working capital and general corporate purposes, particularly to fund operations during its FDA pivotal clinical study [5]. Company Overview - Envoy Medical is focused on innovative hearing health technologies, including the fully implanted Acclaim cochlear implant, which is currently investigational [8].